AstraZeneca’s CEO says his potential 11% pay rise is needed to help the European industry remain competitive with its higher paying US counterparts.

At-home fertility-related hormone test developer Proov sells equity stake to entertainers and expectant parents Ashanti and Nelly; sexual and vaginal health product firm Good Clean Love moves from its founder as leader to a consumer health industry executive.

CEO Paul Hudson says that the French major will continue to progress early-stage cancer projects despite jettisoning some oncology programs in favor of reallocating much of its research budget to immunology.

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.